|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
159,210,000 |
Market
Cap: |
1.34(B) |
Last
Volume: |
2,204,422 |
Avg
Vol: |
2,183,785 |
52
Week Range: |
$3.36 - $8.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 346 |
Guru Rank Value : 6 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Markbreiter Michael |
Director |
|
2015-08-26 |
4 |
S |
$42.78 |
$427,800 |
D/D |
(10,000) |
8,200 |
|
- |
|
Markbreiter Michael |
Director |
|
2015-08-26 |
4 |
OE |
$6.55 |
$65,500 |
D/D |
10,000 |
18,200 |
|
- |
|
Markbreiter Michael |
Director |
|
2015-08-25 |
4 |
S |
$41.67 |
$391,656 |
D/D |
(9,399) |
8,200 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2015-07-08 |
4 |
D |
$45.99 |
$180,097 |
D/D |
(3,916) |
85,694 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2015-05-23 |
4 |
D |
$46.21 |
$50,923 |
D/D |
(1,102) |
89,610 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2015-05-23 |
4 |
D |
$46.21 |
$78,372 |
D/D |
(1,696) |
116,833 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2015-05-15 |
4 |
D |
$44.44 |
$103,545 |
D/D |
(2,330) |
90,712 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2015-05-15 |
4 |
D |
$44.44 |
$61,816 |
D/D |
(1,391) |
69,989 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2015-05-15 |
4 |
D |
$44.44 |
$143,808 |
D/D |
(3,236) |
118,529 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2015-05-14 |
4 |
D |
$44.82 |
$96,946 |
D/D |
(2,163) |
93,042 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2015-05-14 |
4 |
D |
$44.82 |
$96,856 |
D/D |
(2,161) |
71,380 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2015-05-14 |
4 |
D |
$44.82 |
$20,931 |
D/D |
(467) |
70,358 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2015-05-14 |
4 |
D |
$44.82 |
$134,594 |
D/D |
(3,003) |
121,765 |
|
- |
|
Burr Robert L |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,100 |
51,725 |
|
- |
|
Chao Allen |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,100 |
60,695 |
|
- |
|
Fleming Nigel |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,100 |
14,366 |
|
- |
|
Pendergast Mary K |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,100 |
13,600 |
|
- |
|
Hsu Larry |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,100 |
58,251 |
|
- |
|
Terreri Peter R |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,100 |
44,620 |
|
- |
|
Markbreiter Michael |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,100 |
17,599 |
|
- |
|
Benet Leslie Z |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,100 |
9,200 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2015-05-11 |
4 |
D |
$46.10 |
$78,278 |
D/D |
(1,698) |
124,768 |
|
- |
|
Wilkinson George Fred |
Chief Executive Officer |
|
2015-04-29 |
4 |
D |
$46.36 |
$5,322,267 |
D/D |
(114,803) |
459,116 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2015-04-13 |
4 |
D |
$50.90 |
$61,335 |
D/D |
(1,205) |
73,541 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2015-04-08 |
4 |
D |
$51.18 |
$122,013 |
D/D |
(2,384) |
70,825 |
|
- |
|
180 Records found
|
|
Page 6 of 8 |
|
|